Academic partner
of Lymphoma
Clinical Research


LYSARC has the skills, experience and means for conducting all the clinical or ancillary research projects in the lymphoma field, as a partner in the following sectors:Services

  • Academic groups
  • Institutional players
  • Pharma and biotech industries
  • In vitro diagnostics industry
  • Imaging industry

Patient enrolment is primarily conducted within the LYSA network, The Lymphoma Study Association, with its five hundred members within around one hundred centers in four countries (France, Belgium, Portugal, Israel). LYSARC also has numerous collaborations with foreign academic LYSA partners across four continents, when a larger recruitment or histological subtypes of lymphoma make it necessary.

Services offered by LYSARC for a clinical trial include:

  • Project management
  • Legal and finance
  • Methodological advice
  • Study protocol development*
  • Study documents1
  • Regulatory affairs
  • Blood and tumor banking
  • Pre-analytical2 and analytical3 histopathology*
  • Digital pathology*
  • Pathology central review*
  • Imaging central review4*
  • IMP supply
  • Study monitoring
  • Site management and support5
  • Pharmacovigilance
  • Data management
  • Biostatistics6
  • CSR writing
  • Manuscript review
  • Quality assurance7
  • Training8

*  In collaboration with the LYSA experts; 1 All protocols and informed consent forms are reviewed by cancer patients committees of the French Ligue Against Cancer; 2 DNA/RNA extraction, TMA construction; 3 HIC, FISH; 4 PET, TDM, MRI; 5 LYSARC-funded hospital-based and mobile CRAs; 6 CDISC format on request; 7 Includes the non-conformities monitoring process; 8 The Lymphoma Academy

LYSARC benchmarks its efficiency against industry for startup timelines (Re. survey carried out by LEEM -The French Association of Pharmaceutical Companies- on France’s attractiveness for international clinical research): for all measured criteria, LYSARC overperforms versus benchmark .